Document 2875
 DOCN  M94A2875
 TI    Association zidovudine and dipyridamole: a pharmacokinetic study.
 DT    9412
 AU    Livrozet JM; Schrive I; Brunel F; Fournier F; Plasse JC; Touraine JL;
       Hopital E. Herriot, Lyon, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):205 (abstract no. PB0250). Unique
       Identifier : AIDSLINE ICA10/94369700
 AB    OBJECTIVE: Some studies reported dipyridamole potentiates antiviral
       effect of zidovudine (ZDV) by inhibition of thymidine uptake and
       phosphorylation. The aim of this study was to evaluate the effect of the
       association ZDV and dipyridamole in HIV seropositive patients on ZDV
       pharmacokinetic parameters (intracellular and plasmatic concentrations).
       METHODS: Twelve patients were enrolled in this open cross over
       pharmacokinetic study. Patients received 600 mg of ZDV by day during the
       first seven days and 600 mg of ZDV and 450 mg of dipyridamole by day the
       seven following days. We compared ZDV pharmacokinetic parameters (Cmax,
       T max, half-life and AUC) on plasma and on total blood after treatment
       by ZDV alone, and after treatment by ZDV and dipyridamole. RESULTS:
       Results have shown no significant difference on ZDV plasmatic
       concentrations between the 2 periods of treatment. Intracellular
       concentrations are actually performed. DISCUSSION: The association of
       ZDV and dipyridamole could reduce ZDV side effects and treatment costs.
 DE    Dipyridamole/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS/  THERAPEUTIC USE
       Drug Interactions  Drug Therapy, Combination  Half-Life  Human  HIV
       Infections/BLOOD/*DRUG THERAPY  Zidovudine/ADMINISTRATION &
       DOSAGE/*PHARMACOKINETICS/THERAPEUTIC  USE  CLINICAL TRIAL  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).